Ferric Maltol
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ferric Maltol: From Iron Deficiency Anemia to Plummer-Vinson Syndrome
One-Sentence Summary
Ferric maltol is an oral trivalent iron complex established for treating iron deficiency anemia. The TxGNN model predicts it may also be effective for Plummer-Vinson syndrome, a rare iron-deficiency-driven dysphagia disorder, but this direction is currently supported only by mechanistic reasoning — no clinical trials or published literature exist for this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency anemia (per drug mechanism data; no formal indication record in this evidence pack) |
| Predicted New Indication | Plummer-Vinson syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for ferric maltol is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, ferric maltol is an oral Fe³⁺-maltol complex used to treat iron deficiency anemia; its efficacy in that original indication is well established, and mechanistically it may extend to Plummer-Vinson syndrome.
Plummer-Vinson syndrome (iron-deficiency dysphagia syndrome) has chronic iron deficiency anemia as its core etiology, and standard treatment is iron repletion. On this basis, ferric maltol's known efficacy in correcting iron deficiency provides physiological plausibility for benefit in this syndrome.
However, the mechanistic link is indirect: ferric maltol would treat the underlying anemia rather than act directly on the esophageal web/mucosal pathology that defines the syndrome. No drug-specific clinical or literature evidence currently exists to confirm this translates into symptomatic or structural benefit.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA package insert warnings/contraindications (Blocking data gap) and full MOA data (High-severity data gap) are not yet available, which prevents completion of the standard S1 safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on mechanistic plausibility (L4, TxGNN score only) with zero clinical trials or literature support, and a Blocking-severity safety data gap (missing TFDA package insert) currently prevents any safety pre-assessment. The drug is also not marketed in Taiwan.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications data (Blocking gap, DG001)
- Confirmed mechanism of action from DrugBank or primary literature (High-priority gap, DG002)
- Targeted literature search for iron therapy in Plummer-Vinson syndrome (even for iron formulations other than ferric maltol, as supportive class-level evidence)
- Assessment of route/formulation compatibility given the syndrome typically involves dysphagia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.